AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 3 (Table of Contents)
Published: 21 Mar-2015
DOI: 10.3833/pdr.v2015.i3.2099 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Paying a huge premium to acquire an on-market asset with multi billion dollar revenue potential, AbbVie has trumped Johnson & Johnson (J&J) with a US$21 B deal to acquire Pharmacyclics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS